ETAVOPIVAT ONCE DAILY FOR UP TO 12 WKS IS WELL TOLERATED AND IMPROVES ANEMIA IN PATIENTS WITH SCD

Authors
Category Primary study
ConferencePediatric Blood and Cancer
Year 2022
This article has no abstract
Epistemonikos ID: 90928f88db2399418260a2c64401def82b19a35e
First added on: Apr 30, 2026